Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8
|
作者：
Koo, Rachel [1 ]
Lo, Jennifer [2 ]
Bock, Matthew J. [2 ]
机构：
[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA
[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA
来源：
CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期
关键词：
Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;
D O I：
10.1017/S1047951119001082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
引用
下载
收藏
页码：849 / 851
页数：3
相关论文
共 50 条
  • [41] Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series
    Enderby, C. Y.
    Soukup, M.
    Al Omari, M.
    Zeiger, T.
    Burger, C.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (05) : 496 - 500
  • [42] Selexipag for the treatment of pulmonary arterial hypertension
    Skoro-Sajer, Nika
    Lang, Irene Marthe
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (03) : 429 - 436
  • [43] Selexipag for the treatment of pulmonary arterial hypertension
    Genecand, Leon
    Wacker, Julie
    Beghetti, Maurice
    Lador, Frederic
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (05) : 583 - 595
  • [44] Selexipag: A Review in Pulmonary Arterial Hypertension
    Duggan, Sean T.
    Keam, Susan J.
    Burness, Celeste B.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (01) : 73 - 80
  • [45] Selexipag (Uptravi) for Pulmonary Arterial Hypertension
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1488): : 21 - 23
  • [46] Selexipag for the Treatment of Pulmonary Arterial Hypertension
    Sitbon, Olivier
    Channick, Richard
    Chin, Kelly M.
    Frey, Aline
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    Lang, Irene M.
    Preiss, Ralph
    Rubin, Lewis J.
    Di Scala, Lilla
    Tapson, Victor
    Adzerikho, Igor
    Liu, Jinming
    Moiseeva, Olga
    Zeng, Xiaofeng
    Simonneau, Gerald
    McLaughlin, Vallerie V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26): : 2522 - 2533
  • [47] Selexipag: A Review in Pulmonary Arterial Hypertension
    Sean T. Duggan
    Susan J. Keam
    Celeste B. Burness
    American Journal of Cardiovascular Drugs, 2017, 17 : 73 - 80
  • [48] Selexipag for the treatment of pulmonary arterial hypertension
    Noel, Zachary R.
    Kido, Kazuhiko
    Macaulay, Tracy E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (15) : 1135 - 1141
  • [49] Selexipag for the treatment of pulmonary arterial hypertension
    Richter, Manuel Jonas
    Gall, Henning
    Grimminger, Jan
    Grimminger, Friedrich
    Ghofrani, Hossein-Ardeschir
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) : 1825 - 1834
  • [50] Selexipag for the treatment of pulmonary arterial hypertension
    Sharma, Kamal
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (01) : 1 - 3
12345